Study on the therapeutic and nursing effect of thrombus targeted thrombolysis mediated by recombinant plasminogen activator modified nanoparticles on stroke patients

Abstract

Tissue plasminogen activator (rt-PA) is a thrombolytic drug used for the treatment of stroke. However, it has a short half-life and a high risk of complications of cerebral hemorrhage, which complicates its use in clinical applications. In this study, polyethylene glycol and polycaprolactone were used as nano-carriers in the development of new nano-drug-recombinant plasminogen activator modified nanoparticles (PEG-PCL@rt-PA) loaded with rt-PA. Following treatment, the patients received with either conventional nursing or continuous nursing. Compared with traditional treatment and nursing, the nanoparticles had stronger thrombolytic and therapeutic effects, significantly improved the self-care recovery rate of patients, and reduced the occurrence of complications. This new mode of PEG-PCL@rt-PA drug therapy combined with continuous nursing is expected to improve the recovery and survival rates of stroke patients.